A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
← catalyst calendarNCT07233239 · readout in 467 d
Sponsored by Jazz Pharmaceuticals (industry) · JAZZ — their whole pipeline →. With Jazz Pharmaceuticals Research UK Ltd..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
24
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-26 | actual | When the study began enrolling |
| Primary completion | 2027-11-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Focal Seizures
Intervention
- Drug: CBD-OS — also filed as GWP42003-P, JZP926
Primary outcome
what the primary-completion date above is the date OFPercent change in countable focal seizure frequency compared to baseline
measured Baseline up to 16 weeks
Permalink · JAZZ's whole pipeline · Catalyst calendar · Every registered study · What changed